Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review

Abstract Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common pathological subtype of pancreatic cancer, usually has poor therapeutic results. Immune checkpoint inhibitors (ICIs) can relie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hong-Bo Li, Zi-Han Yang, Qing-Qu Guo
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Pancreatic ductal adenocarcinoma Immune checkpoint inhibitors Tumor microenvironment Medicine R Cytology QH573-671
Acceso en línea:	https://doaj.org/article/406634dabe0244e6958f3f3e3ac6d2be
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:406634dabe0244e6958f3f3e3ac6d2be
record_format	dspace
spelling	oai:doaj.org-article:406634dabe0244e6958f3f3e3ac6d2be2021-11-28T12:13:48ZImmune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review10.1186/s12964-021-00789-w1478-811Xhttps://doaj.org/article/406634dabe0244e6958f3f3e3ac6d2be2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12964-021-00789-whttps://doaj.org/toc/1478-811XAbstract Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common pathological subtype of pancreatic cancer, usually has poor therapeutic results. Immune checkpoint inhibitors (ICIs) can relieve failure of the tumor-killing effect of immune effector cells caused by immune checkpoints. Therefore, they have been used as a novel treatment for many solid tumors. However, PDAC is not sensitive to monotherapy with ICIs, which might be related to the inhibitory immune microenvironment of pancreatic cancer. Therefore, the way to improve the microenvironment has raised a heated discussion in recent years. Here, we elaborate on the relationship between different immune cellular components in this environment, list some current preclinical or clinical attempts to enhance the efficacy of ICIs by targeting the inhibitory tumor microenvironment of PDAC or in combination with other therapies. Such information offers a better understanding of the sophisticated tumor-microenvironment interactions, also providing insights on therapeutic guidance of PDAC targeting. Video AbstractHong-Bo LiZi-Han YangQing-Qu GuoBMCarticlePancreatic ductal adenocarcinomaImmune checkpoint inhibitorsTumor microenvironmentMedicineRCytologyQH573-671ENCell Communication and Signaling, Vol 19, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Pancreatic ductal adenocarcinoma Immune checkpoint inhibitors Tumor microenvironment Medicine R Cytology QH573-671
spellingShingle	Pancreatic ductal adenocarcinoma Immune checkpoint inhibitors Tumor microenvironment Medicine R Cytology QH573-671 Hong-Bo Li Zi-Han Yang Qing-Qu Guo Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
description	Abstract Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common pathological subtype of pancreatic cancer, usually has poor therapeutic results. Immune checkpoint inhibitors (ICIs) can relieve failure of the tumor-killing effect of immune effector cells caused by immune checkpoints. Therefore, they have been used as a novel treatment for many solid tumors. However, PDAC is not sensitive to monotherapy with ICIs, which might be related to the inhibitory immune microenvironment of pancreatic cancer. Therefore, the way to improve the microenvironment has raised a heated discussion in recent years. Here, we elaborate on the relationship between different immune cellular components in this environment, list some current preclinical or clinical attempts to enhance the efficacy of ICIs by targeting the inhibitory tumor microenvironment of PDAC or in combination with other therapies. Such information offers a better understanding of the sophisticated tumor-microenvironment interactions, also providing insights on therapeutic guidance of PDAC targeting. Video Abstract
format	article
author	Hong-Bo Li Zi-Han Yang Qing-Qu Guo
author_facet	Hong-Bo Li Zi-Han Yang Qing-Qu Guo
author_sort	Hong-Bo Li
title	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
title_short	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
title_full	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
title_fullStr	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
title_full_unstemmed	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
title_sort	immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
publisher	BMC
publishDate	2021
url	https://doaj.org/article/406634dabe0244e6958f3f3e3ac6d2be
work_keys_str_mv	AT hongboli immunecheckpointinhibitionforpancreaticductaladenocarcinomalimitationsandprospectsasystematicreview AT zihanyang immunecheckpointinhibitionforpancreaticductaladenocarcinomalimitationsandprospectsasystematicreview AT qingquguo immunecheckpointinhibitionforpancreaticductaladenocarcinomalimitationsandprospectsasystematicreview
_version_	1718408133369397248

Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review

Ejemplares similares